Alnylam Pharma (DUL) Q3 2023 Earnings Report
0 Followers
CH:DUL Q3 2023 EPS Results
- Actual EPS
- CHF 0.94
- Consensus EPS
- -CHF 1.18
- Beat/Miss
- Beat by +CHF 2.11
- One Year Ago EPS
- -CHF 2.70
CH:DUL Q3 2023 Revenue Results
- Actual Revenue
- CHF 611.13M
- Expected Revenue
- CHF 323.06M
- Beat/Miss
- Beat by +CHF 288.06M
- YoY Revenue Growth
- +183.96%
Earnings Announcement Details
- Quarter
- Q3 2023
- Date
- 11/02/2023
- Time
- Before Open
- Conference Call
- Thursday, November 2, 2023
CH:DUL Upcoming Earnings
Alnylam Pharma's next earnings date is estimated for February 18, 2027, based on past reporting schedules.
Q3 2023 Earnings Call Audio
CH:DUL Q3 2023 Earnings Call
0:00 / 0:00
Q3 2023 Earnings Slide Deck
Q3 2023 Earnings Call Summary
No earnings call summary is available for this earnings event.
CH:DUL Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 18, 2027 | 2026 (Q4) | 1.40- | 0.67 | ― | ― |
| Oct 29, 2026 | 2026 (Q3) | 1.3512.80 | 1.5 | 754.35% (+11.30) | |
| Jul 30, 2026 | 2026 (Q2) | 1.330.99 | -0.42 | 337.25% (+1.40) | |
| Apr 30, 2026 | 2026 (Q1) | 0.711.23 | -0.36 | 443.18% (+1.59) | |
| Feb 12, 2026 | 2025 (Q4) | 0.940.67 | -0.53 | 226.15% (+1.20) | |
| Oct 30, 2025 | 2025 (Q3) | 0.461.50 | -0.71 | 311.49% (+2.21) | |
| Jul 31, 2025 | 2025 (Q2) | -0.44-0.42 | -0.11 | -292.31% (-0.31) | |
| May 01, 2025 | 2025 (Q1) | -0.72-0.36 | -0.42 | 15.38% (+0.07) | |
| Feb 13, 2025 | 2024 (Q4) | -0.48-0.53 | -0.9 | 40.91% (+0.37) | |
| Oct 31, 2024 | 2024 (Q3) | -0.75-0.71 | 0.94 | -175.65% (-1.64) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat Missed
